The estimated Net Worth of Ernest Loumaye is at least $3.73 Million dollars as of 6 April 2023. Ernest Loumaye owns over 4,000,000 units of ObsEva SA stock worth over $1,000,000 and over the last 2 years he sold OBSV stock worth over $0. In addition, he makes $2,725,000 as Chief Executive Officer and Director at ObsEva SA.
Sign up
Ernest Loumaye OBSV stock SEC Form 4 insiders trading
Ernest has made over 2 trades of the ObsEva SA stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 4,000,000 units of OBSV stock worth $400,000 on 6 April 2023.
The largest trade he's ever made was buying 4,000,000 units of ObsEva SA stock on 6 April 2023 worth over $400,000. On average, Ernest trades about 4,000,000 units every 18 days since 2023. As of 6 April 2023 he still owns at least 10,000,000 units of ObsEva SA stock.
You can see the complete history of Ernest Loumaye stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ernest Loumaye biography
Dr. Ernest Loumaye M.D., Ph.D. serves as Chief Executive Officer, Director of the Company. serves as Chief Executive Officer, Director of the Company. Previously, Dr. Loumaye is a co-founder of our company and has served as our Chief Executive Officer since our inception in November 2012. Since September 2019, he is also a member of the board of directors at AVA, a Zurich-based company active in all areas of women's health. Previously, Dr. Loumaye co-founded PregLem, a Swiss specialty biopharmaceutical company sold to Gedeon Richter Plc., and served as its Chief Executive Officer and member of the board of directors from 2006 to October 2012. From 2011 to 2016, Dr. Loumaye served as chairperson and member of the board at Genkyotex, a public biopharmaceutical company developing treatments against various diseases based on enzyme inhibition. Dr. Loumaye holds an M.D. and a Ph.D. from University of Louvain, Belgium, with a specialization in Obstetrics and Gynaecology.
What is the salary of Ernest Loumaye?
As the Chief Executive Officer and Director of ObsEva SA, the total compensation of Ernest Loumaye at ObsEva SA is $2,725,000. There are 1 executives at ObsEva SA getting paid more, with Brian O'Callaghan having the highest compensation of $4,289,000.
How old is Ernest Loumaye?
Ernest Loumaye is 67, he's been the Chief Executive Officer and Director of ObsEva SA since 2012. There are 1 older and 15 younger executives at ObsEva SA. The oldest executive at ObsEva SA. is Dr. Ernest Loumaye, 69, who is the Co-Founder & Director.
What's Ernest Loumaye's mailing address?
Ernest's mailing address filed with the SEC is C/O OBSEVA SA, C/O CHEMIN DES AULX, 12, PLAN-LES-OUATES, GENEVA, V8, 1228.
Insiders trading at ObsEva SA
Over the last 2 years, insiders at ObsEva SA have traded over $0 worth of ObsEva SA stock and bought 8,000,000 units worth $840,000 . The most active insiders traders include Ernest Loumaye. On average, ObsEva SA executives and independent directors trade stock every 18 days with the average trade being worth of $400,000. The most recent stock trade was executed by Ernest Loumaye on 6 April 2023, trading 4,000,000 units of OBSV stock currently worth $400,000.
What does ObsEva SA's logo look like?
Complete history of Ernest Loumaye stock trades at ObsEva SA
ObsEva SA executives and stock owners
ObsEva SA executives and other stock owners filed with the SEC include:
-
Brian O'Callaghan,
CEO & Director -
Ernest Loumaye,
Chief Executive Officer, Director -
Dr. Ernest Loumaye,
Co-Founder & Director -
Jacky Vonderscher,
Independent Director -
Rafaele Tordjman,
Independent Director -
Edward Mathers,
Independent Director -
James Healy,
Independent Director -
Barbara Duncan,
Independent Director -
Annette Clancy,
Independent Director -
Wim Souverijns,
Chief Commercial Officer -
Elizabeth Garner,
Chief Medical Officer -
Jean-Pierre Gotteland,
Chief Scientific Officer, Head of Research & Development -
Frank Verwiel,
Independent Chairman of the Board -
Luigi Marro,
Chief Transformation Officer -
Clive Bertram,
Chief Commercial Officer -
Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H.,
Chief Medical Officer -
Delphine Renaud,
Personal Assistant to the CSO and Head of R&D -
Mario Vincent Corso,
Sr. Director of Investor Relations -
Fabien Lefebvre de Ladonchamps,
Chief Admin. Officer -
Dr. Jean-Pierre Gotteland Ph.D.,
Chief Scientific Officer and Head of R&D -
William Michael Brown,
Chief Financial Officer -
William Michael Brown,
Interim CEO and CFO